Published in J Clin Microbiol on June 01, 2004
HIV incidence determination in the United States: a multiassay approach. J Infect Dis (2012) 2.47
Detection of recent HIV-1 infection using a new limiting-antigen avidity assay: potential for HIV-1 incidence estimates and avidity maturation studies. PLoS One (2012) 2.41
Incorrect identification of recent HIV infection in adults in the United States using a limiting-antigen avidity assay. AIDS (2014) 2.18
Use of a multifaceted approach to analyze HIV incidence in a cohort study of women in the United States: HIV Prevention Trials Network 064 Study. J Infect Dis (2012) 1.78
Factors associated with incorrect identification of recent HIV infection using the BED capture immunoassay. AIDS Res Hum Retroviruses (2011) 1.66
Human immunodeficiency virus (HIV) antibody avidity testing to identify recent infection in newly diagnosed HIV type 1 (HIV-1)-seropositive persons infected with diverse HIV-1 subtypes. J Clin Microbiol (2006) 1.64
Specificity of four laboratory approaches for cross-sectional HIV incidence determination: analysis of samples from adults with known nonrecent HIV infection from five African countries. AIDS Res Hum Retroviruses (2012) 1.50
Use of a high resolution melting (HRM) assay to compare gag, pol, and env diversity in adults with different stages of HIV infection. PLoS One (2011) 1.46
Trends of HIV-1 seroincidence among HIV-1 sentinel surveillance groups in Cambodia, 1999-2002. J Acquir Immune Defic Syndr (2005) 1.43
A comparison of biomarker based incidence estimators. PLoS One (2009) 1.41
Estimation of HIV incidence in a large, community-based, randomized clinical trial: NIMH project accept (HIV Prevention Trials Network 043). PLoS One (2013) 1.40
Performance of a limiting-antigen avidity enzyme immunoassay for cross-sectional estimation of HIV incidence in the United States. PLoS One (2013) 1.37
Effect of natural and ARV-induced viral suppression and viral breakthrough on anti-HIV antibody proportion and avidity in patients with HIV-1 subtype B infection. PLoS One (2013) 1.35
Acute HIV-1 infection is highly prevalent in Ugandan adults with suspected malaria. AIDS (2010) 1.32
Cross-sectional HIV incidence estimation in HIV prevention research. J Acquir Immune Defic Syndr (2013) 1.31
Development of methods for cross-sectional HIV incidence estimation in a large, community randomized trial. PLoS One (2013) 1.24
Estimation of HIV-1 incidence among five focal populations in Dehong, Yunnan: a hard hit area along a major drug trafficking route. BMC Public Health (2010) 1.23
Timing and order of transmission events is not directly reflected in a pathogen phylogeny. Mol Biol Evol (2014) 1.08
Seroincidence of recent human immunodeficiency virus type 1 infections in China. Clin Vaccine Immunol (2007) 1.06
Impact of HIV subtype on performance of the limiting antigen-avidity enzyme immunoassay, the bio-rad avidity assay, and the BED capture immunoassay in Rakai, Uganda. AIDS Res Hum Retroviruses (2013) 1.05
Towards estimation of HIV-1 date of infection: a time-continuous IgG-model shows that seroconversion does not occur at the midpoint between negative and positive tests. PLoS One (2013) 1.04
Analysis of HIV using a high resolution melting (HRM) diversity assay: automation of HRM data analysis enhances the utility of the assay for analysis of HIV incidence. PLoS One (2012) 1.02
Comparison of the human immunodeficiency virus (HIV) type 1-specific immunoglobulin G capture enzyme-linked immunosorbent assay and the avidity index method for identification of recent HIV infections. J Clin Microbiol (2007) 0.96
Prevalence, estimated HIV-1 incidence and viral diversity among people seeking voluntary counseling and testing services in Rio de Janeiro, Brazil. BMC Infect Dis (2010) 0.96
HIV diversity as a biomarker for HIV incidence estimation: including a high-resolution melting diversity assay in a multiassay algorithm. J Clin Microbiol (2013) 0.95
Evaluation of the false recent classification rates of multiassay algorithms in estimating HIV type 1 subtype C incidence. AIDS Res Hum Retroviruses (2013) 0.92
Social network-based recruitment successfully reveals HIV-1 transmission networks among high-risk individuals in El Salvador. J Acquir Immune Defic Syndr (2013) 0.92
Antibody Maturation in Women Who Acquire HIV Infection While Using Antiretroviral Preexposure Prophylaxis. J Infect Dis (2015) 0.91
Developing high-throughput HIV incidence assay with pyrosequencing platform. J Virol (2013) 0.91
Changes in HIV incidence among people who inject drugs in Taiwan following introduction of a harm reduction program: a study of two cohorts. PLoS Med (2014) 0.91
The effect of sample handling on cross sectional HIV incidence testing results. PLoS One (2011) 0.90
Differential specificity of HIV incidence assays in HIV subtypes A and D-infected individuals from Rakai, Uganda. AIDS Res Hum Retroviruses (2013) 0.90
HIV incidence estimate combining HIV/AIDS surveillance, testing history information and HIV test to identify recent infections in Lazio, Italy. BMC Infect Dis (2012) 0.90
A comprehensive evaluation of the proficiency testing program for the HIV-1 BED incidence assay. J Clin Microbiol (2011) 0.89
HIV-1 diversity and drug resistance mutations among people seeking HIV diagnosis in voluntary counseling and testing sites in Rio de Janeiro, Brazil. PLoS One (2014) 0.89
Low incidences of human immunodeficiency virus and hepatitis C virus infection and declining risk behaviors in a cohort of injection drug users in Chennai, India. Am J Epidemiol (2010) 0.89
Association of recent HIV infection and in-utero HIV-1 transmission. AIDS (2011) 0.89
Antibody maturation and viral diversification in HIV-infected women. PLoS One (2013) 0.88
Evaluation of a multiplex assay for estimation of HIV-1 incidence. PLoS One (2013) 0.87
Pregnancy does not affect HIV incidence test results obtained using the BED capture enzyme immunoassay or an antibody avidity assay. PLoS One (2010) 0.86
Immune responses in Ugandan women infected with subtypes A and D HIV using the BED capture immunoassay and an antibody avidity assay. J Acquir Immune Defic Syndr (2014) 0.84
Assessment of BED HIV-1 incidence assay in seroconverter cohorts: effect of individuals with long-term infection and importance of stable incidence. PLoS One (2011) 0.82
The potential role of biomarkers in HIV preventive vaccine trials. J Acquir Immune Defic Syndr (2009) 0.81
Inter-laboratory assessment of a prototype multiplex kit for determination of recent HIV-1 infection. PLoS One (2013) 0.81
Association of pol diversity with antiretroviral treatment outcomes among HIV-infected African children. PLoS One (2013) 0.81
Analysis of Viral Diversity in Relation to the Recency of HIV-1C Infection in Botswana. PLoS One (2016) 0.81
A comparison of two measures of HIV diversity in multi-assay algorithms for HIV incidence estimation. PLoS One (2014) 0.80
Screening for acute HIV infections and estimating HIV incidence among female sex workers from low-grade venues in Guangxi, China. PLoS One (2014) 0.80
Incidence of recent human immunodeficiency virus infection at two voluntary counseling testing centers in Pernambuco, Brazil, from 2006 to 2009. J Clin Microbiol (2012) 0.79
Development of a proficiency testing program for the HIV-1 BED incidence assay in China. Sci Rep (2014) 0.79
Estimated incidence and genotypes of HIV-1 among pregnant women in central Brazil. PLoS One (2013) 0.78
Mean Recency Period for Estimation of HIV-1 Incidence with the BED-Capture EIA and Bio-Rad Avidity in Persons Diagnosed in the United States with Subtype B. PLoS One (2016) 0.78
Current and future assays for identifying recent HIV infections at the population level. Med Sci Monit (2011) 0.78
Development and Evaluation of a Modified Fourth-Generation Human Immunodeficiency Virus Enzyme Immunoassay for Cross-Sectional Incidence Estimation in Clade B Populations. AIDS Res Hum Retroviruses (2016) 0.77
Trends of HIV-1 incidence with credible intervals in Sweden 2002-09 reconstructed using a dynamic model of within-patient IgG growth. Int J Epidemiol (2015) 0.77
Recent HIV-1 infection: identification of individuals with high viral load setpoint in a voluntary counselling and testing centre in rural Mozambique. PLoS One (2012) 0.77
Molecular Epidemiology and Transmission Dynamics of Recent and Long-Term HIV-1 Infections in Rural Western Kenya. PLoS One (2016) 0.77
Viral and Host Characteristics of Recent and Established HIV-1 Infections in Kisumu based on a Multiassay Approach. Sci Rep (2016) 0.75
Comparison of cross-sectional HIV incidence assay results from dried blood spots and plasma. PLoS One (2017) 0.75
The Impact of Viral Suppression and Viral Breakthrough on Limited-Antigen Avidity Assay Results in Individuals with Clade B HIV Infection. AIDS Res Hum Retroviruses (2016) 0.75
Impact of early antiretroviral therapy on the performance of HIV rapid tests and HIV incidence assays. J Acquir Immune Defic Syndr (2017) 0.75
New testing strategy to detect early HIV-1 infection for use in incidence estimates and for clinical and prevention purposes. JAMA (1998) 9.32
Quantitative detection of increasing HIV type 1 antibodies after seroconversion: a simple assay for detecting recent HIV infection and estimating incidence. AIDS Res Hum Retroviruses (2002) 7.03
Performance characteristics of a new less sensitive HIV-1 enzyme immunoassay for use in estimating HIV seroincidence. J Acquir Immune Defic Syndr (2003) 3.14
Feasibility of pooling sera for HIV-1 viral RNA to diagnose acute primary HIV-1 infection and estimate HIV incidence. AIDS (2000) 2.37
Development of a new less-sensitive enzyme immunoassay for detection of early HIV-1 infection. J Acquir Immune Defic Syndr (2003) 2.21
Evaluation of a sensitive/less sensitive testing algorithm using the bioMérieux Vironostika-LS assay for detecting recent HIV-1 subtype B' or E infection in Thailand. AIDS Res Hum Retroviruses (2003) 2.04
Differential maturation of avidity of IgG antibodies to gp41, p24 and p17 following infection with HIV-1. Clin Exp Immunol (1996) 1.90
Evaluation of a sensitive/less-sensitive testing algorithm using the 3A11-LS assay for detecting recent HIV seroconversion among individuals with HIV-1 subtype B or E infection in Thailand. AIDS Res Hum Retroviruses (2001) 1.81
Detection of primary HIV infection by a second-generation HIV(p24) antigen test. Infusionsther Transfusionsmed (1994) 1.59
Assessment of antibody assays for identifying and distinguishing recent from long-term HIV type 1 infection. AIDS Res Hum Retroviruses (2001) 1.44
HIV seroincidence among patients at clinics for sexually transmitted diseases in nine cities in the United States. J Acquir Immune Defic Syndr (2002) 1.37
Test of HIV incidence shows continuing HIV transmission in homosexual/bisexual men in England and Wales. Commun Dis Public Health (2001) 1.01
Utility of an HIV-1 RNA assay in the diagnosis of acute retroviral syndrome. South Med J (2000) 0.94
Quantitative detection of increasing HIV type 1 antibodies after seroconversion: a simple assay for detecting recent HIV infection and estimating incidence. AIDS Res Hum Retroviruses (2002) 7.03
Intermittent prophylaxis with oral truvada protects macaques from rectal SHIV infection. Sci Transl Med (2010) 5.85
Complete protection from repeated vaginal simian-human immunodeficiency virus exposures in macaques by a topical gel containing tenofovir alone or with emtricitabine. J Virol (2009) 4.73
Comparison of HIV type 1 incidence observed during longitudinal follow-up with incidence estimated by cross-sectional analysis using the BED capture enzyme immunoassay. AIDS Res Hum Retroviruses (2006) 3.74
Improved HIV-1 incidence estimates using the BED capture enzyme immunoassay. AIDS (2008) 3.32
Determination of mean recency period for estimation of HIV type 1 Incidence with the BED-capture EIA in persons infected with diverse subtypes. AIDS Res Hum Retroviruses (2010) 2.86
Exposure to substances in the workplace and new-onset asthma: an international prospective population-based study (ECRHS-II). Lancet (2007) 2.74
Coupled mRNA stabilization and translational silencing of cyclooxygenase-2 by a novel RNA binding protein, CUGBP2. Mol Cell (2003) 2.46
Detection of recent HIV-1 infection using a new limiting-antigen avidity assay: potential for HIV-1 incidence estimates and avidity maturation studies. PLoS One (2012) 2.41
Prevention and early intervention of anxiety disorders in inhibited preschool children. J Consult Clin Psychol (2005) 2.40
Guidelines for performing single-platform absolute CD4+ T-cell determinations with CD45 gating for persons infected with human immunodeficiency virus. Centers for Disease Control and Prevention. MMWR Recomm Rep (2003) 2.28
Decreased hepatic triglyceride accumulation and altered fatty acid uptake in mice with deletion of the liver fatty acid-binding protein gene. J Biol Chem (2003) 2.15
HIV type 1 incidence estimates by detection of recent infection from a cross-sectional sampling of injection drug users in Bangkok: use of the IgG capture BED enzyme immunoassay. AIDS Res Hum Retroviruses (2003) 1.68
Evaluation of an alternative HIV diagnostic algorithm using specimens from seroconversion panels and persons with established HIV infections. J Clin Virol (2011) 1.66
Performance of the OraQuick and Hema-Strip rapid HIV antibody detection assays by non-laboratorians. J Clin Virol (2004) 1.64
Durable protection from vaginal simian-human immunodeficiency virus infection in macaques by tenofovir gel and its relationship to drug levels in tissue. J Virol (2011) 1.56
Development of two avidity-based assays to detect recent HIV type 1 seroconversion using a multisubtype gp41 recombinant protein. AIDS Res Hum Retroviruses (2010) 1.53
Performance of an alternative laboratory-based algorithm for HIV diagnosis in a high-risk population. J Clin Virol (2011) 1.52
Applying public health strategies to primary immunodeficiency diseases: a potential approach to genetic disorders. MMWR Recomm Rep (2004) 1.52
Surveillance for HIV-1 incidence using tests for recent infection in resource-constrained countries. AIDS (2005) 1.51
The impact of high-dose statin therapy on transendothelial neutrophil migration and serum cholesterol levels in healthy male volunteers. Eur J Clin Pharmacol (2011) 1.49
Application of laboratory methods for estimation of HIV-1 incidence. Indian J Med Res (2005) 1.47
Detection of human immunodeficiency virus type 1 DNA in dried blood spots by a duplex real-time PCR assay. J Clin Microbiol (2005) 1.44
Compensatory increase in hepatic lipogenesis in mice with conditional intestine-specific Mttp deficiency. J Biol Chem (2005) 1.43
Trends of HIV-1 seroincidence among HIV-1 sentinel surveillance groups in Cambodia, 1999-2002. J Acquir Immune Defic Syndr (2005) 1.43
Prevention of vaginal SHIV transmission in macaques by a coitally-dependent Truvada regimen. PLoS One (2012) 1.42
Natural substrate concentrations can modulate the prophylactic efficacy of nucleotide HIV reverse transcriptase inhibitors. J Virol (2011) 1.38
Modification of rapid human immunodeficiency virus (HIV) antibody assay protocols for detecting recent HIV seroconversion. Clin Diagn Lab Immunol (2005) 1.35
Correlating transcriptional networks to breast cancer survival: a large-scale coexpression analysis. Carcinogenesis (2013) 1.32
Infiltration of forest fire and residential wood smoke: an evaluation of air cleaner effectiveness. J Expo Sci Environ Epidemiol (2007) 1.28
Prevalence and prognostic and predictive relevance of PRAME in breast cancer. Breast Cancer Res Treat (2007) 1.22
Bcl-B expression in human epithelial and nonepithelial malignancies. Clin Cancer Res (2008) 1.16
Effect of mobile phase pH and organic content on LC-MS analysis of nucleoside and nucleotide HIV reverse transcriptase inhibitors. J Chromatogr Sci (2009) 1.16
Human immunodeficiency virus (HIV) seropositivity among uninfected HIV vaccine recipients. J Infect Dis (2003) 1.15
Prediction of anxiety symptoms in preschool-aged children: examination of maternal and paternal perspectives. J Child Psychol Psychiatry (2009) 1.13
Expression of multidrug resistance markers ABCB1 (MDR-1/P-gp) and ABCC1 (MRP-1) in renal cell carcinoma. BMC Urol (2009) 1.12
Safety and pharmacokinetics of intravaginal rings delivering tenofovir in pig-tailed macaques. Antimicrob Agents Chemother (2012) 1.11
BED estimates of HIV incidence must be adjusted. AIDS (2009) 1.11
Tumor-associated alterations in caspase-14 expression in epithelial malignancies. Clin Cancer Res (2005) 1.11
Safe and sustained vaginal delivery of pyrimidinedione HIV-1 inhibitors from polyurethane intravaginal rings. Antimicrob Agents Chemother (2011) 1.10
Helicobacter pylori induces plasminogen activator inhibitor 2 in gastric epithelial cells through nuclear factor-kappaB and RhoA: implications for invasion and apoptosis. Cancer Res (2004) 1.09
Evaluating the BED capture enzyme immunoassay to estimate HIV incidence among adults in three countries in sub-Saharan Africa. AIDS Res Hum Retroviruses (2010) 1.08
A novel nuclear localization signal in the auxiliary domain of apobec-1 complementation factor regulates nucleocytoplasmic import and shuttling. J Biol Chem (2003) 1.07
Unsafe injections and transmission of HIV-1 in sub-Saharan Africa. Lancet (2004) 1.07
Evaluation of rapid prenatal human immunodeficiency virus testing in rural cameroon. Clin Diagn Lab Immunol (2005) 1.07
On-line coupling of anion exchange and ion-pair chromatography for measurement of intracellular triphosphate metabolites of reverse transcriptase inhibitors. J Chromatogr B Analyt Technol Biomed Life Sci (2009) 1.06
Targeted deletion of the murine apobec-1 complementation factor (acf) gene results in embryonic lethality. Mol Cell Biol (2005) 1.05
HIV testing in developing countries: what is required? Indian J Med Res (2011) 1.04
Postexposure protection of macaques from vaginal SHIV infection by topical integrase inhibitors. Sci Transl Med (2014) 1.03
Service learning in neuroscience courses. J Undergrad Neurosci Educ (2012) 1.02
Rapid detection of HIV-1 p24 antigen using magnetic immuno-chromatography (MICT). J Virol Methods (2009) 1.01
Lack of prophylactic efficacy of oral maraviroc in macaques despite high drug concentrations in rectal tissues. J Virol (2013) 0.99
Investigation of MRP-1 protein and MDR-1 P-glycoprotein expression in invasive breast cancer: a prognostic study. Int J Cancer (2004) 0.98
Matrix metalloproteinase 26 proteolysis of the NH2-terminal domain of the estrogen receptor beta correlates with the survival of breast cancer patients. Cancer Res (2006) 0.97
Transmitted drug resistance and type of infection in newly diagnosed HIV-1 individuals in Honduras. J Clin Virol (2010) 0.96
Cervical spine injury is highly dependent on the mechanism of injury following blunt and penetrating assault. J Trauma (2006) 0.93
Occupational exposure to immunologically active agents and risk for lymphoma. Cancer Epidemiol Biomarkers Prev (2004) 0.93
A critical evaluation of enzyme immunoassay kits for detection of antinuclear autoantibodies of defined specificities. III. Comparative performance characteristics of academic and manufacturers' laboratories. J Rheumatol (2003) 0.93
Conditional intestinal lipotoxicity in Apobec-1-/- Mttp-IKO mice: a survival advantage for mammalian intestinal apolipoprotein B mRNA editing. J Biol Chem (2007) 0.93
Identification of pancreatic cancer invasion-related proteins by proteomic analysis. Proteome Sci (2009) 0.93
Decreased expression of cholesterol 7alpha-hydroxylase and altered bile acid metabolism in Apobec-1-/- mice lead to increased gallstone susceptibility. J Biol Chem (2009) 0.93
Inflammatory myofibroblastic tumor of the nose and paranasal sinuses masquerading as a malignancy. Ear Nose Throat J (2012) 0.93
Deletion of the AU-rich RNA binding protein Apobec-1 reduces intestinal tumor burden in Apc(min) mice. Cancer Res (2007) 0.92
Highly sensitive assay for human herpesvirus 8 antibodies that uses a multiple antigenic peptide derived from open reading frame K8.1. J Clin Microbiol (2002) 0.91
C-->U editing of neurofibromatosis 1 mRNA occurs in tumors that express both the type II transcript and apobec-1, the catalytic subunit of the apolipoprotein B mRNA-editing enzyme. Am J Hum Genet (2001) 0.91
Pain in people with an intellectual disability. Curr Opin Psychiatry (2013) 0.90
A comprehensive evaluation of the proficiency testing program for the HIV-1 BED incidence assay. J Clin Microbiol (2011) 0.89
MAGE-D4B is a novel marker of poor prognosis and potential therapeutic target involved in breast cancer tumorigenesis. Int J Cancer (2011) 0.89
Differential expression of fourteen proteins between uveal melanoma from patients who subsequently developed distant metastases versus those who did Not. Invest Ophthalmol Vis Sci (2012) 0.89
Genome-wide identification and functional analysis of Apobec-1-mediated C-to-U RNA editing in mouse small intestine and liver. Genome Biol (2014) 0.89
Thoracolumbar fracture in blunt trauma: is clinical exam enough for awake patients? J Trauma (2006) 0.87
Current HIV-2 diagnostic strategy overestimates HIV-2 prevalence in China. J Med Virol (2009) 0.86
Evaluation of IGF1R and phosphorylated IGF1R as targets in HER2-positive breast cancer cell lines and tumours. Breast Cancer Res Treat (2012) 0.85
Drug metabolism-related genes as potential biomarkers: analysis of expression in normal and tumour breast tissue. Breast Cancer Res Treat (2007) 0.85
Apobec-1 complementation factor modulates liver regeneration by post-transcriptional regulation of interleukin-6 mRNA stability. J Biol Chem (2010) 0.85
Inhibition of Hedgehog signaling protects adult mice from diet-induced weight gain. J Nutr (2004) 0.85
Raised plasma endostatin levels correlate inversely with breast cancer angiogenesis. J Surg Res (2004) 0.85
The purple line as a measure of labour progress: a longitudinal study. BMC Pregnancy Childbirth (2010) 0.83
Beware the empty curette! Orbit (2002) 0.82
Does volume matter? The effect of trauma surgeons' caseload on mortality. J Trauma (2003) 0.82
Assessment of BED HIV-1 incidence assay in seroconverter cohorts: effect of individuals with long-term infection and importance of stable incidence. PLoS One (2011) 0.82
UC781 microbicide gel retains anti-HIV activity in cervicovaginal lavage fluids collected following twice-daily vaginal application. Antimicrob Agents Chemother (2012) 0.82
Development of a novel rapid HIV test for simultaneous detection of recent or long-term HIV type 1 infection using a single testing device. AIDS Res Hum Retroviruses (2013) 0.82
Association of scapular fractures and blunt thoracic aortic injury: fact or fiction? Am Surg (2005) 0.81
Lumbar fractures in adult blunt trauma: axial and single-slice helical abdominal and pelvic computed tomographic scans versus portable plain films. J Trauma (2002) 0.81
Intestine-specific expression of Apobec-1 rescues apolipoprotein B RNA editing and alters chylomicron production in Apobec1 -/- mice. J Lipid Res (2012) 0.81
Hepatic Mttp deletion reverses gallstone susceptibility in L-Fabp knockout mice. J Lipid Res (2014) 0.81
Liver X receptor agonist modulation of cholesterol efflux in mice with intestine-specific deletion of microsomal triglyceride transfer protein. Arterioscler Thromb Vasc Biol (2012) 0.80
Incidence of presumed postoperative endophthalmitis in Dublin for a 5-year period (1997--2001). J Cataract Refract Surg (2005) 0.80
Liver fatty acid-binding protein (L-Fabp) modifies intestinal fatty acid composition and adenoma formation in ApcMin/+ mice. Cancer Prev Res (Phila) (2013) 0.80
Pharmacokinetic evaluation of tenofovir disoproxil fumarate released from an intravaginal ring in pigtailed macaques after 6 months of continuous use. J Med Primatol (2014) 0.80
Traumatic injuries to the portal vein: case study. J Trauma (2004) 0.79
Excess of symptoms among radiographers. Am J Ind Med (2003) 0.79
Demographic and immune correlates of human herpesvirus 8 seropositivity in Malawi, Africa. Int J Infect Dis (2002) 0.79
Intestine-Specific Mttp Deletion Increases the Severity of Experimental Colitis and Leads to Greater Tumor Burden in a Model of Colitis Associated Cancer. PLoS One (2013) 0.78
EGFR and HER2 inhibition in pancreatic cancer. Invest New Drugs (2012) 0.78
Cysteine sulfinic acid decarboxylase regulation: A role for farnesoid X receptor and small heterodimer partner in murine hepatic taurine metabolism. Hepatol Res (2013) 0.78
A critical evaluation of enzyme immunoassay kits for detection of antinuclear autoantibodies of defined specificities. II. Potential for quantitation of antibody content. J Rheumatol (2002) 0.78